Inna Yuryev-Golger, MD
Psychiatry · Brooklyn, NYNPI 1053324780
Payments from drug & device makers
Across 521 payments — averaging $5812.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$639K
- Sage Therapeutics, LLC$580K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$346K
- Avanir Pharmaceuticals, Inc.$346K
- H. Lundbeck A S$275K
- AbbVie$192K
- plus $650K from 14 others
Across 12 payments — averaging $89.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Acadia Pharmaceuticals Inc$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 81 | $638,879 |
| Sage Therapeutics, LLC | 85 | $579,966 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 19 | $346,401 |
| Avanir Pharmaceuticals, Inc. | 31 | $345,718 |
| H. Lundbeck A S | 13 | $275,495 |
| AbbVie(2 entities) | 43 | $192,425 |
| Teva Pharmaceuticals USA, Inc. | 42 | $159,772 |
| Ipsen Innovation | 99 | $154,637 |
| Acadia Pharmaceuticals Inc | 23 | $145,396 |
| Eli Lilly | 7 | $65,729 |
| Merz Pharmaceuticals, LLC | 8 | $42,680 |
| Eisai Inc. | 17 | $21,816 |
| Biohaven Pharmaceutical Holding Company Ltd. | 31 | $21,146 |
| Boehringer Ingelheim | 3 | $19,812 |
| Genentech, Inc. | 3 | $8,337 |
| Biohaven Pharmaceuticals, Inc. | 6 | $5,347 |
| Boehringer Ingelheim International GmbH | 6 | $4,072 |
| Dr.reddy's Laboratories,inc. | 1 | $836 |
| Vanda Pharmaceuticals Inc. | 2 | $32 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
How this compares
$3,028,513 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other psychiatry in Brooklyn
- Zinoviy BenzarBrooklyn$505K
- Nikhil PalekarBrooklyn$481K
- Mark OwensBrooklyn$286K
- Elyssa BarronWhite Plains$12.8M
- Mark DibuonoStaten Island$11.9M
- Ronald BrennerHempstead$11.5M
- Anton PorsteinssonRochester$7.6M
- Michael LiebowitzNew York$7.1M
- Leslie CitromePomona$5.7M
- John KaneGlen Oaks$4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.